Efficacy of praziquantel drug against Schistosoma haematobium and performance of urine reagent strips among pre-and-school aged children during the high transmission season in North-Western Tanzania.

Cure Rates Efficacy Egg Reduction Rate Praziquantel Schistosoma haematobium Schistosomiasis Tanzania high season pre-and-school aged children

Journal

Acta tropica
ISSN: 1873-6254
Titre abrégé: Acta Trop
Pays: Netherlands
ID NLM: 0370374

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 16 11 2023
revised: 18 04 2024
accepted: 26 04 2024
medline: 11 5 2024
pubmed: 11 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

The World Health Organization calls for schistosomiasis endemic countries to regularly monitor the efficacy of Praziquantel (PZQ) drug, the only antischistosomal drug used for four decades in Tanzania. In response to that call, the current study investigated the efficacy of single dose of PZQ against Schistosoma haematobium during the high transmission season and further assessed, the sensitivity and specificity of urine reagent strips before and after treatment. The study recruited a total of 2,498 -children aged (4 -17 years old) who provided a single urine sample that was visually examined for macro-haematuria, then using urine dipstick and urine filtration technique for microhaematuria and the presence of S. haematobium eggs. The baseline prevalence of S. haematobium eggs positive based on urine filtration test was 29.2%(95%CI:27.5-31.0) and that of microhaematuria was 43.1% (95%CI:41.1-45.0). Of the infected participants, 40.9%(95%CI:37.4-44.6) had a heavy intensity of infection and the geometrical mean intensity (GMI) of infection was 33.7 eggs/10mls of urine. A single dose of PZQ reduced the prevalence of infection to 16.2%, the GMI of infection to 18.8eggs/10mls of urine and that of microhaematuria to 27.9%. Cure rate and egg reduction rates (ERR) were 83.8% and 44.3% respectively. At baseline, the sensitivity and specificity of the urine reagent strips were 59.7% and 93.8%, whereas at post-treatment they were 16.7% and 93.6%. When PZQ drug is administered during the high transmission season, its efficacy in term of ERR is poor. The urine reagent strips had low sensitivity but high specificity at pre-and-post PZQ treatment.

Identifiants

pubmed: 38729329
pii: S0001-706X(24)00114-1
doi: 10.1016/j.actatropica.2024.107232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107232

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Humphrey Deogratias Mazigo reports financial support, administrative support, and statistical analysis were provided by National Institute for Health Research. Humphrey Mazigo reports a relationship with Catholic University of Health and Allied Sciences that includes: employment. None has patent pending to None. None If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Humphrey D Mazigo (HD)

Tackling Infections to Benefit Africa Partnership and School of Public Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania; Tackling Infections to Benefit Africa Partnership, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom. Electronic address: humphreymazigo@gmail.com.

Neema Kayange (N)

Tackling Infections to Benefit Africa Partnership and Department of Paediatrics and Child Health, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania.

Emmanuela E Ambrose (EE)

Tackling Infections to Benefit Africa Partnership and Department of Paediatrics and Child Health, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania.

Maria M Zinga (MM)

Tackling Infections to Benefit Africa Partnership and School of Public Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania.

Stella Mugassa (S)

Tackling Infections to Benefit Africa Partnership and School of Public Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania.

Deodatus Ruganuza (D)

Tackling Infections to Benefit Africa Partnership and School of Public Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania.

Upendo J Mwingira (UJ)

National Neglected Tropical Diseases Control Programme, National Institute for Medical Research, P.O. Box 9653, 3 Barack Obama Drive, 11101 Dar-Es-Salaam, Tanzania.

Cecilia Uisso (C)

National Neglected Tropical Diseases Control Programme, National Institute for Medical Research, P.O. Box 9653, 3 Barack Obama Drive, 11101 Dar-Es-Salaam, Tanzania.

Francesca Mutapi (F)

Tackling Infections to Benefit Africa Partnership, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom; Institute of Immunology and Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Classifications MeSH